Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2113-2123

  Hime, Neil J ^a,b   Black, Audrey S ^a   Bulgrien, Josh J ^a   Curtiss, Linda K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CETPtgLDLr mice; Cholesteryl ester transfer protein; High density lipoproteins; High fat feeding; Macrophages

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUKOCYTE DERIVED HEPATIC LIGASE; LIGASE; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; LIPID DIET; LIPOPROTEIN DEFICIENCY; MACROPHAGE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, DIETARY; DIETARY FATS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES; LIPASE; LIPOPROTEINS, HDL; MALE; MICE; MICE, TRANSGENIC; RECEPTORS, LDL; SINUS OF VALSALVA;

EID: 67649781177     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700564-JLR200     Document Type: Article

References (48)

1. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
2. Williams, K. J., and I. Tabas. 1998. The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol. 9: 471-474.
3. Nong, Z., H. Gonzalez-Navarro, M. Amar, L. Freeman, C. Knapper, E. B. Neufeld, B. J. Paigen, R. F. Hoyt, J. Fruchart-Najib, and S. Santamarina-Fojo. 2003. Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCATtransgenic mice. J. Clin. Invest. 112: 367-378.
4. Zhang, Z., S. Yamashita, K. Hirano, Y. Nakagawa-Toyama, A. Matsuyama, M. Nishida, N. Sakai, M. Fukasawa, H. Arai, J. Miyagawa, et al. 2001. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis. 159: 67-75.
5. Yla-Herttuala, S., B. A. Lipton, M. E. Rosenfeld, I. J. Goldberg, D. Steinberg, and J. L. Witztum. 1991. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 88: 10143-10147.
6. O'Brien, K. D., D. Gordon, S. Deeb, M. Ferguson, and A. Chait. 1992. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J. Clin. Invest. 89: 1544-1550.
7. O'Brien, K. D., S. Vuletic, T. O. McDonald, G. Wolfbauer, K. Lewis, A. Y. Tu, S. Marcovina, T. N. Wight, A. Chait, and J. J. Albers. 2003. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 108: 270-274.
8. Laffitte, B. A., S. B. Joseph, M. Chen, A. Castrillo, J. Repa, D. Wilpitz, D. Mangelsdorf, and P. Tontonoz. 2003. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23: 2182-2191.
9. Desrumaux, C. M., P. A. Mak, W. A. Boisvert, D. Masson, D. Stupack, M. Jauhiainen, C. Ehnholm, and L. K. Curtiss. 2003. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J. Lipid Res. 44: 1453-1461.
10. Curtiss, L. K., D. T. Valenta, N. J. Hime, and K. A. Rye. 2006. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler. Thromb. Vasc. Biol. 26: 12-19.
11. Valenta, D. T., N. Ogier, G. Bradshaw, A. S. Black, D. J. Bonnet, L. Lagrost, L. K. Curtiss, and C. M. Desrumaux. 2006. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler. Thromb. Vasc. Biol. 26: 1572-1578.
12. Van Eck, M., D. Ye, R. B. Hildebrand, J. Kar Kruijt, W. de Haan, M. Hoekstra, P. C. Rensen, C. Ehnholm, M. Jauhiainen, and T. J. Van Berkel. 2007. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in ldl receptor knockout mice. Circ. Res. 100: 678-685.
13. Vikstedt, R., D. Ye, J. Metso, R. B. Hildebrand, T. J. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck. 2007. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler. Thromb. Vasc. Biol. 27: 578-586.
14. Hopkins, G. J., and P. J. Barter. 1980. Transfers of esterified cholesterol and triglyceride between high density and very low density lipoproteins: in vitro studies of rabbits and humans. Metabolism. 29: 546-550.
15. Rye, K. A., N. J. Hime, and P. J. Barter. 1995. The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins. J. Biol. Chem. 270: 189-196.
16. Shirai, K., R. L. Barnhart, and R. L. Jackson. 1981. Hydrolysis of human plasma high density lipoprotein 2-phospholipids and triglycerides by hepatic lipase. Biochem. Biophys. Res. Commun. 100: 591-599.
17. Clay, M. A., H. H. Newnham, T. M. Forte, and P. J. Barter. 1992. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim. Biophys. Acta. 1124: 52-58.
18. Hirano, K., S. Yamashita, Y. Kuga, N. Sakai, S. Nozaki, S. Kihara, T. Arai, K. Yanagi, S. Takami, M. Menju, et al. 1995. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15: 1849-1856.
19. Boisvert, W. A., J. Spangenberg, and L. K. Curtiss. 1995. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J. Clin. Invest. 96: 1118-1124.
20. Hocquette, J. F., B. Graulet, and T. Olivecrona. 1998. Lipoprotein lipase activity and mRNA levels in bovine tissues. Comp. Biochem. Physiol. B. 121: 201-212.
21. Bairaktari, E., M. Elisaf, A. Katsaraki, V. Tsimihodimos, A. D. Tselepis, K. C. Siamopoulos, and O. Tsolas. 1999. Homogeneous HDL-cholesterol assay versus ultracentrifugation/dextran sulfateMg2+ precipitation and dextran sulfate-Mg2+ precipitation in healthy population and in hemodialysis patients. Clin. Biochem. 32: 339-346.
22. Warnick, G. R., J. Benderson, and J. J. Albers. 1982. Dextran sulfateMg2+ precipitation procedure for quantitation of high-densitylipoprotein cholesterol. Clin. Chem. 28: 1379-1388.
23. Valenta, D. T., J. J. Bulgrien, C. L. Banka, and L. K. Curtiss. 2006. Overexpression of human apoAI transgene provides long-term atheroprotection in LDL receptor-deficient mice. Atherosclerosis. 189: 255-263.
24. Mullick, A. E., P. S. Tobias, and L. K. Curtiss. 2005. Modulation of atherosclerosis in mice by toll-like receptor 2. J. Clin. Invest. 115: 3149-3156.
25. Schiller, N. K., N. Kubo, W. A. Boisvert, and L. K. Curtiss. 2001. Effect of gamma-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21: 1674-1680.
26. Jiang, X. C., L. B. Agellon, A. Walsh, J. L. Breslow, and A. Tall. 1992. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J. Clin. Invest. 90: 1290-1295.
27. Warren, R. J., D. L. Ebert, P. J. Barter, and A. Mitchell. 1991. The regulation of hepatic lipase and cholesteryl ester transfer protein activity in the cholesterol fed rabbit. Biochim. Biophys. Acta. 1086: 354-358.
28. Petrovan, R. J., C. D. Kaplan, R. A. Reisfeld, and L. K. Curtiss. 2007. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 1095-1100.
29. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364: 73-75.
30. Plump, A. S., L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A. R. Tall. 1999. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19: 1105-1110.
31. Mezdour, H., R. Jones, C. Dengremont, G. Castro, and N. Maeda. 1997. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein Edeficient mice. J. Biol. Chem. 272: 13570-13575.
32. Rye, K. A., M. A. Clay, and P. J. Barter. 1999. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis. 145: 227-238.
33. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15.
34. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
35. von Eckardstein, A., J. R. Nofer, and G. Assmann. 2001. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21: 13-27.
36. Rashid, S., T. Watanabe, T. Sakaue, and G. F. Lewis. 2003. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin. Biochem. 36: 421-429.
37. Gonzalez-Navarro, H., Z. Nong, L. Freeman, A. Bensadoun, K. Peterson, and S. Santamarina-Fojo. 2002. Identification of mouse and human macrophages as a site of synthesis of hepatic lipase. J. Lipid Res. 43: 671-675.
38. Lambert, G., M. J. Amar, P. Martin, J. Fruchart-Najib, B. Foger, R. D. Shamburek, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2000. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. J. Lipid Res. 41: 667-672.
39. Rashid, S., D. K. Trinh, K. D. Uffelman, J. S. Cohn, D. J. Rader, and G. F. Lewis. 2003. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I. Circulation. 107: 3066-3072.
40. Peterson, J., G. Bengtsson-Olivecrona, and T. Olivecrona. 1986. Mouse preheparin plasma contains high levels of hepatic lipase with low affinity for heparin. Biochim. Biophys. Acta. 878: 65-70.
41. Clay, M. A., H. H. Newnham, and P. J. Barter. 1991. Hepatic lipase promotes a loss of apolipoprotein A-I from triglyceride-enriched human high density lipoproteins during incubation in vitro. Arterioscler. Thromb. 11: 415-422.
42. Birjmohun, R. S., B. A. Hutten, J. J. Kastelein, and E. S. Stroes. 2005. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 45: 185-197.
43. Bloomfield Rubins, H., J. Davenport, V. Babikian, L. M. Brass, D. Collins, L. Wexler, S. Wagner, V. Papademetriou, G. Rutan, and S. J. Robins. 2001. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 103: 2828-2833.
44. Tall, A. R., L. Yvan-Charvet, and N. Wang. 2007. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27: 257-260.
45. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406: 203-207.
46. Rittershaus, C. W., D. P. Miller, L. J. Thomas, M. D. Picard, C. M. Honan, C. D. Emmett, C. L. Pettey, H. Adari, R. A. Hammond, D. T. Beattie, et al. 2000. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2106-2112.
47. Kastelein, J. J., S. I. van Leuven, L. Burgess, G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, C. L. Shear, et al. 2007. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356: 1620-1630.
48. Nissen, S. E., J. C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, and E. M. Tuzcu. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356: 1304-1316.